Oxelumab
 | This article relies largely or entirely on a single source. (January 2024) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | OX-40 ligand |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2014S42 |
| Molar mass | 144594.46 g·mol−1 |
  (what is this?) (verify) | |
Oxelumab is a human monoclonal antibody designed for the treatment of asthma.[1]
Oxelumab was developed by Genentech and co-developed by Roche.
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab" (PDF). American Medical Association. Archived from the original (PDF) on 12 May 2013.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |